Holen Sie sich die Stockscreener-App
13.70
0.29%
-0.04
Vorhandelsmarkt:
13.70
Schlusskurs vom Vortag:
$13.74
Offen:
$13.77
24-Stunden-Volumen:
617.12K
Relative Volume:
0.61
Marktkapitalisierung:
$835.49M
Einnahmen:
$13.73M
Nettoeinkommen (Verlust:
$-114.48M
KGV:
-7.4384
EPS:
-1.8418
Netto-Cashflow:
$-78.49M
1W Leistung:
+0.59%
1M Leistung:
-1.37%
6M Leistung:
-6.48%
1J Leistung:
-41.97%
1-Tages-Spanne:
$13.63
$13.96
1-Wochen-Bereich:
$12.98
$14.03
52-Wochen-Spanne:
$12.12
$35.34
Janux Therapeutics Inc Stock (JANX) Company Profile
Firmenname
Janux Therapeutics Inc
Sektor
Branche
Telefon
(858) 751-4493
Adresse
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
13.70 | 837.93M | 13.73M | -114.48M | -78.49M | -1.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Herabstufung | Barclays | Overweight → Underweight |
| 2026-04-15 | Herabstufung | UBS | Buy → Neutral |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-10 | Eingeleitet | Stifel | Buy |
| 2025-09-10 | Eingeleitet | Truist | Buy |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-07-11 | Eingeleitet | Raymond James | Outperform |
| 2024-12-03 | Bestätigt | BTIG Research | Buy |
| 2024-12-03 | Bestätigt | H.C. Wainwright | Buy |
| 2024-11-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-09-06 | Eingeleitet | Stifel | Buy |
| 2024-05-30 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-03-21 | Eingeleitet | BTIG Research | Buy |
| 2024-03-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-06 | Eingeleitet | Wedbush | Outperform |
| 2022-11-14 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Janux Therapeutics Inc Aktie (JANX) Neueste Nachrichten
Behavioral Patterns of JANX and Institutional Flows - Stock Traders Daily
JANX SEC FilingsJanux Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Top Cybin (HELP) Competitors 2026 - MarketBeat
Janux Therapeutics (JANX) details RSU and stock option grants to RA Capital–linked entities - Stock Titan
Janux Therapeutics (JANX) director reports RSU and option awards tied to RA Capital - Stock Titan
Janux Therapeutics (JANX) awards director RSUs and 15,500 options - Stock Titan
Janux Therapeutics (JANX) director awarded RSUs and stock options - Stock Titan
Director at Janux Therapeutics (JANX) gets new RSUs and stock options - Stock Titan
Janux Therapeutics Reports Results of 2026 Annual Meeting - TipRanks
Shareholders back Janux Therapeutics (NASDAQ: JANX) board and pay - Stock Titan
Janux Therapeutics, Inc. (JANX) reports Q1 loss, lags revenue estimates - MSN
How much upside is left in Janux Therapeutics (JANX)? Wall Street analysts think 180.44% - MSN
Janux Therapeutics (JANX) Q1 2026 Earnings: Better-than-Expected Loss Reduction Highlights Pipeline ProgressNew Analyst Coverage - newsline.com
JANX News | JANUX THERAPEUTICS INC (NASDAQ:JANX) - ChartMill
B of A Securities Maintains Janux Therapeutics (JANX) Buy Recommendation - MSN
JANX Technical Analysis & Stock Price Forecast - Intellectia AI
Janux Therapeutics officer Janeen Doyle sells $56,943 in stock By Investing.com - Investing.com Australia
(JANX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Janux Therapeutics officer Janeen Doyle sells $56,943 in stock - Investing.com UK
Janux Therapeutics (JANX) officer auto-sells 4,059 shares to cover RSU taxes - Stock Titan
4,059 RSUs to be Sold by JANX (NASDAQ: JANX) - Stock Titan
JANX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Janux Therapeutics Q1 2026 Earnings: Narrower Loss Surprises, Stock Edges LowerEarnings Power Value - thelegaladvocate.com
Janux Therapeutics, Inc.Common Stock (NQ: JANX - FinancialContent
Wall Street analysts predict a 155.82% upside in Janux Therapeutics (JANX): Here's what you should know - MSN
Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know - Yahoo Finance
JANX: Janux TherapeuticsPrice & Consenus Chart - Zacks Investment Research
Here's Why You Should Add JANX Stock to Your Portfolio Now - TradingView
JANX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
How (JANX) Movements Inform Risk Allocation Models - Stock Traders Daily
Analyst Reiterates Buy on Janux Therapeutics, Citing Deep Pipeline Catalysts and Compelling Risk/Reward at Near-Zero Enterprise Value - TipRanks
JANX Q1 2026 Earnings: Narrowed Loss Beats Estimates; Clinical Pipeline Progress UnderwayManagement Tone Analysis - newsline.com
Janux secures $35 million milestone payment from Bristol Myers Squibb - MSN
Janux Therapeutics (JANX) price target decreased by 14.60% to 42.12 - MSN
Janus Henderson (JANX) discloses 4.2M shares, 6.9% passive stake - Stock Titan
Trading Systems Reacting to (JANX) Volatility - Stock Traders Daily
Insider Sell: Maria Dobek Sells Shares of Janux Therapeutics Inc (JANX) - GuruFocus
Janux Therapeutics VP Maria Dobek sells $28,878 in stock By Investing.com - Investing.com Australia
Janux Therapeutics VP Maria Dobek sells $28,878 in stock - Investing.com
Janux Therapeutics (JANX) VP sells 2,038 shares at $14.17 - Stock Titan
Bullish: Analysts Just Made A Meaningful Upgrade To Their Janux Therapeutics, Inc. (NASDAQ:JANX) Forecasts - simplywall.st
Finanzdaten der Janux Therapeutics Inc-Aktie (JANX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):